Caris Life Sciences Inc., of Irving, Texas, announced a collaboration with the National Cancer Institute for the NCI-Molecular Analysis for Therapy Choice, NCI-MATCH or EAY131 precision medicine trial, which is being implemented by the ECOG-ACRIN Cancer Research Group.